Patent · US Active

Target-specific CRISPR mutant

US12351838B2 · kind B2 · utility

0Cited by
0References
11Claims
0Family size

Assignee

Inventors

Key dates

Filing dateApr 26, 2019
Grant dateJul 8, 2025
Priority date
Expiry dateOct 8, 2041

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12R2001/46
  • WIPO fieldBiotechnology
  • WIPO sectorChemistry

Abstract

The present invention relates to an artificially engineered CRISPR/Cas9 system. More particularly, the present invention relates to an artificially engineered CRISPR enzyme having enhanced target specificity and a use of an artificially engineered CRISPR/Cas9 system including the same enzyme in genome and/or epigenome manipulation or modification, genome targeting, genome editing, and in vitro diagnosis, etc.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.